Estradiol delivery by vaginal rings: Potential for hormone replacement therapy

Maturitas

Volumn 26, Issue 1, 1997, Pages 27-33

  Nash, Harold A ^a   Brache, Vivian ^b   Alvarez Sanchez, Francisco ^b   Jackanicz, Theodore M ^a   Harmon, Troy M ^c  

^a POPULATION COUNCIL   (United States)

^b PROFAMILIA   (Dominican Republic)

^c FEI Technologies   (United States)

Author keywords

blood levels; estradiol; estrogen replacement; postmenopausal; vaginal rings

Indexed keywords

ESTRADIOL; ESTROGEN;

ADULT; ARTICLE; BONE ATROPHY; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ESTROGEN DEFICIENCY; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; POSTMENOPAUSE;

ADMINISTRATION, INTRAVAGINAL; CLIMACTERIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED;

EID: 0031052130     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01072-9     Document Type: Article

References (20)

1. Belchetz PE. Hormonal treatment of postmenopausal women. New Engl J Med 1994; 330: 1062-1071.
2. Henriksson L, Sjernquist M, Bosquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low dose estradiol released from a new vaginal ring versus estradiol vaginal pessaries in post menopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994; 171: 624-632.
3. Meisels A. The maturation value. Acta Cytol 1967; 11: 249.
4. Pschera H, Hjerpe A, Carlström K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 β and progesterone in postmenopausal women. Gynecol Obstet Invest 1989; 27: 204-207.
5. Englund DE, Victor A, Johansson EDB. Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from Silastic rings in post-menopausal women. Maturitis 1981; 3: 125-133.
6. Padwick ML, Endacott J, Whitehead MI. Efficacy, acceptability and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-1091.
7. Scott RT, Ross B, Andersen C, Archer D. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991; 77: 758-764.
8. Steingold KA, Laufer L, Chetkowski RJ, DeFazio JD, Matt DW, Meldrum DR, Judd HL. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985; 61: 627-632.
9. Wiklund I, Karlberg J, Mattsson L-A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168: 824-830.
10. Haas S, Walsh B, Evans S, Krache M, Ravnikar V, Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988; 71: 671-676.
11. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 114-121.
12. Selby PL, Peacock M. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Br Med J 1986; 293: 1337-1339.
13. Selby PL, McGarrigle HHG, Peacock M. Comparison of the effect of oral and transdermal oestradiol administration on oestradiol metabolism, protein synthesis, gonadotropin release, bone turnover, and climacteric symptoms in postmenopausal women. Clin Endocrinol 1989: 30: 241-249.
14. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of normal estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159: 1540-1546.
15. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 β-estradiol: comparisons with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
16. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
17. Cicenelli E, Galantino P, Pepe V, Papolizio A, Savino F, Balzano G, Epifani S, Cantatore PP. Bone metabolism studies after transdermal estradiol dose reduction during estrogen replacement therapy. A 1 year prospective study. Maturitis 1994; 19: 133-139.
18. Lindsay R. Hormonc replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993; 95 Suppl. 5A: 37S-39S.
19. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Studies 1993; 38 Suppl.: 30-35.
20. Studd JWW, Holland EFN, Leather AT, Smith RNJ. The dose response of percutaneous estradiol implants on the skeleton of postmenopausal women. Br J Obstet Gynecol 1994; 101: 787-791.